A Safety and Immunogenicity Phase 1 Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31) Administered at 0 and 2 Months.
Latest Information Update: 08 Nov 2021
At a glance
- Drugs Tuberculosis vaccine (Primary) ; H1IC
- Indications Tuberculosis
- Focus Adverse reactions
- Sponsors Statens Serum Institut
Most Recent Events
- 07 Nov 2009 New trial record